Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, TRI

SAGA Diagnostics enters into an assay development agreement with AstraZeneca


LUND, Sweden, Nov. 2, 2021 /CNW/ -- SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN). 

SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies.

We have chosen to partner with SAGA because of the ultrasensitive performance of the SAGAsafe® technology and possibility to custom tailor highly complex dPCR assays to meet our desired analytical standards. We are excited about exploring this new area together with SAGA.

? James Hadfield, Director Epigenomics, Oncology Translational Medicine, Oncology R&D, AstraZeneca

SAGAsafe® is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods and can be used to quantify sequence variants in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance. 

We are honored that Dr. Hadfield and his team have selected SAGA and the SAGAsafe® platform to develop ultrasensitive dPCR methylation assays for AstraZeneca's clinical research study, and are pleased to be working together again.

? Lao Saal, co-founder and COO of SAGA Diagnostics

SAGAsafe® is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign® for personalized monitoring of cancer burden and minimal residual disease (MRD) using chromosomal rearrangements, as well as novel technologies in development. SAGA offers both off-the-shelf analysis services and kits as well as customizable solutions to fit customers' needs.  SAGA's molecular tools are being used in clinical trials and hospitals for detecting actionable mutations, monitoring treatment response, measuring minimal residual disease, and identifying resistance mechanisms to help direct therapy.

Contact: COO Lao Saal, MD PhD, [email protected], Phone: +46(0)733-01-7242

About SAGA Diagnostics AB

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive "liquid biopsies" such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity and provides the basis for optimal decision-making. https://sagadiagnostics.com/.

Follow us on Twitter @SAGAdiagnostics and LinkedIn.

Logo - https://mma.prnewswire.com/media/1553032/SAGA_Diagnostics_Logo.jpg

 

SOURCE SAGA Diagnostics


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
Bidpath Inc., a leading provider of global online auction software, proudly announces the launch of AuctionPay, a cutting-edge payments platform designed to revolutionize auction payments. With a focus on efficiency, security, and user-centric...

at 08:00
SC Ventures, Standard Chartered's innovation, fintech investment and ventures arm, is leading a ?12 million (USD $13 million) Series A round for distributed cloud provider Hive, to increase access to sustainable, high-powered computing resources for...

at 08:00
Callon Petroleum Company ("Callon" or the "Company") today announced the expiration and final tender results of its previously announced cash tender offers (the "Offers") for any and all of its 8.000% Senior Notes due 2028 (the "2028 Notes") and any...

at 08:00
The parties in Severa, et al. v. Solvay Specialty Polymers USA, LLC, et al., announce that Judge Noel Hillman of the United States District Court for the District of New Jersey has preliminarily approved a class action settlement. The hearing on...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: